Drug–drug interactions in general hospital and psychiatric hospital in-patients prescribed psychotropic medications

References

• Raschetti R, Morgutti M, Menniti-Ippolito F, Belisari A, Rossignoli A, Longhini P, . Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol 1999;54(12):959–63.
   Google Scholar
• Becker M, Kallewaard M, Caspers P, Visser L, Leufkens H, Stricker B. Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiology and drug safety 2007;16:641–51.
   PubMed Web of Science ®Google Scholar
• Sikka R, Magauran B, Ulrich A, Shannon M. Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system. Acad Emerg Med 2005;12(12): 1227–35.
   Google Scholar
• Leape L, Bates D, Cullen D, Cooper J, Demonaco H, Gallivan T, . Systems analysis of adverse drug events. ADE Prevention Study Group. J Am Med Assoc 1995; 274(1):35–43.
   Google Scholar
• Aparasu R, Baer R, Aparasu A. Clinically important potential drug–drug interactions in outpatient settings. Res Social Adm Pharm 2007;3(4):426–37.
   Google Scholar
• Tulner LR, Frankfort SV, Gijsen GJP, van Campen JPC, Koks CHW, Beijnen JH. Drug–drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging 2008;25(4):343–55.
   Google Scholar
• Becker, Visser L, van Gelder T, Hofman A, Stricker B. Increasing exposure to drug–drug interactions between 1992 and 2005 in people aged > or = 55 years. Drugs Aging 2008; 25(2):145–52.
   Google Scholar
• Haider S, Johnell K, Thorslund K, Fastbom J. Trends in polypharmacy and potential drug–drug interactions across educational groups in elderly patients in Sweden for the period 1992–2002. Int J Clin Pharmacol Ther 2007;45(12): 643–53.
   Google Scholar
• Bjerrum L, Andersen M, Petersen G, Kragstrup J. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003;21(3):153–8.
   Google Scholar
• Johnell K, Klarin I. The relationship between number of drugs and potential drug–drug interactions in the elderly: a study of over 600,000 patients from the Swedish Prescribed Drug Register. Drug Saf 2007;30(10):911–8.
   Google Scholar
• Johnell K, Klarin I. The relationship between number of drugs and potential drug–drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 2007;30(10):911–8.
   Google Scholar
• Aronson JK, Henderson G, Webb DJ, Rawlins MD. A prescription for better prescribing. Br Med J 2006;333(7566): 459–60.
   Google Scholar
• Rosenbaum J. Managing selective serotonin reuptaje inhibitor-drug interactions in clinical practice. Clin Pharmacokinet 1995;29(Suppl 1):53–9.
   Google Scholar
• Davies S, Eayrs S, Pratt P, Lennard M. Potential for drug interactions involving cytochrome P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol 2004;57(4):464–72.
   Google Scholar
• Astrand E, Astrand B, Antonov K, Petersson G. Potential drug interactions during a three-decade study period: a cross sectional study of a prescription register. Eur J Clin Pharmacol 2007;63:851–9.
   PubMed Web of Science ®Google Scholar
• Gagne J, Maio V, Rabinowitz C. Prevalence and predictors of potential drug–drug interactions in Regione Emilia-Romagna, Italy. J Clin Pharmacol Ther 2008;33:141–51.
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future. J Psychopharmacol 2006 Jul 1;20(Suppl 4):85–94.
   Google Scholar
• Markowitz J, Devine C. Drug interaction potential of fluoxetine, sertraline and paroxetine in four state psychiatric hospital populations. Ther Drug Monit 1997;19(2):244–5.
   Google Scholar
• Sakhuja D, Bisson J. Liaison psychiatry services in Wales. Psychiatr Bull 2008;32:134–6.
   Google Scholar
• Gomez J. Liaison psychiatry. Mental health problems in the general hospital. London: Croom-Helm; 1987.
   Google Scholar
• Peveler R, House A. Developing services in liaison psychiatry; making the case of need. Liaison psychiatry: Planning services for specialist settings. London: Gaskell; 2000. 1–13.
   Google Scholar
• Torem M, Saravay S, Steinberg H. Psychiatric liaison: benefits of an “active” approach. Psychosomatics 1979;20(9):598–611.
   Google Scholar
• Kornfeld D. Consultation-liaison psychiatry: Contributions to medical practice. Am J Psychiatry 2002;159(1964):1972.
   Google Scholar
• Howe A, Hendry J, Potokar JPP. A survey of liaison psychiatry services in the south-west of England. Psychiatr Bull 2003;27:90–2.
   Google Scholar
• Klimke A, Klieser R. Sudden death after intravenous application of lorazepam in a patient treated with clozapine. Am J Psychiatry 1994;151(5):780.
   Google Scholar
• Jackson C, Markowitz J, Brewerton T. Delirium associated with clozapine and benzodiazepine combinations. Ann Clin Psychiatry 1995;7(3):139–41.
   Google Scholar
• Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K. Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: Plasma level-correlated symptomatology. J Clin Psychopharmacol 2002;22(4):440–1.
   Google Scholar
• Kesevan S, Sobala G. Serotonin syndrome with fluoxetine plus tramadol. J R Soc Med 1999;92(9):474–5.
   Google Scholar
• Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther 2007;29(11 Suppl 1):2477–97.
   Google Scholar
• Hemeryck A, Belpaire F. Selective serotonin reuptake inhibitors and cytochrome P450 mediated drug–drug interactions: An update. Curr Drug Metab 2002;3(1):13–37.
   Google Scholar
• Dalma-Weiszhausz D, Murphy GJ. Single nucleotide polymorphisms and their characterisation with oligonucleotide microarrays. Psychiatr Genet 2002;12(2):97–107.
   Google Scholar
• Humphries T, Carroll N, Chester E, Magid D, Rocho B. Evaluation of an electronic critical drug interactions program compared with active pharmacist intervention. Ann Pharmacother 2007;41(12):1979–85.
   Google Scholar
• Blix H, Viktil K, Moger T, Reikvam A. Identification of drug interactions in hospitals-computerised screening vs. bedside recording. J Clin Pharmacol Ther 2008;33:131–9.
   Google Scholar
• Egger T, Dormann H, Runge U, Neubert A, Criegge-Rieck M, Gassmann K, . Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging 2003;20(10):769–76.
   Google Scholar
• Dallenbach M, Bovier P, Desmeules J. Detecting drug interactions using personal digital assistants in an out-patient clinic. Q J Med 2007;100:691–7.
   Google Scholar
• Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE. Drug interactions in primary care: Impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004;76(1):85–96.
   Google Scholar
• Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug–drug interactions among elderly patients hospitalized for drug toxicity. J Am Med Assoc 2003;289(13): 1652–8.
   Google Scholar
• Preskorn S. Drug–drug Interactions: Proof of relevance (Part I). J Psychiatr Pract 2005;11(2):116–23.
   Google Scholar
• DeVane C. Antidepressant-drug interactions are potentially but rarely clinically significant. Neuropsychopharmacology 2006;31(8):1594–604.
   Google Scholar
• Davies SJC, Jackson PR, Ramsay LE, Ghahramani P. Drug intolerance due to nonspecific adverse effects related to psychiatric morbidity in hypertensive patients. Arch Intern Med 2003;163(5):592–600.
   Google Scholar
• Brosen K, Naranjo C. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001;11:275–83.
   PubMed Web of Science ®Google Scholar
• Evans W, Relling M. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorpan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolisers. Pharmacogenetics 1991;1(3):143–8.
   Google Scholar
• Masimirembwa C, Hasler J, Bertilssons L, Johansson I, Ekberg O, Ingelam-Sundberg M. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 1996;51(2):117–22.
   Google Scholar
• Chou WH, Yan FX, Robbins-Weilert DK, Ryder TB, Liu WW, Perbost C, . Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 2003;49(4):542–51.
   Google Scholar
• Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer U. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10(8):545–58.
   Google Scholar
• Chou W, Yan F, de Leon J, Barnhill J, Rogers T, Cronin M, . Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. Clin Psychopharmacol 2000;20(2): 246–51.
   Google Scholar
• de Leon J, Barnhill J, Rogers T, Boyle J, Chou WH, Wedlund PJ. Pilot Study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am J Psychiatry 1998;155(9): 1278–80.
   Google Scholar